Li Mao-Lin, Wu Gui-Jie, Zhou Zhen-Huan, Zheng Lian-Wen, Xu Ying, Bao Yi-Gang, Wang Yong-Jun, Dai Xiao-Wei
Center of Reproductive Medicine, The Second Hospital of Jilin University， Changchun, Jilin 130022, China.
Department of Urology, Shaoxing Second Hospital, Shaoxing, Zhejiang 312000, China.
Zhonghua Nan Ke Xue. 2020 Jun;26(6):543-546.
To observe the clinical effect of Yihechun Capsules (YHC) on oligozoospermia and asthenospermia.
A total of 181 male patients with infertility were randomly divided into a YHC+Levocarnitine (LC) group (n = 93, including 42 cases of oligozoospermia, 20 cases of asthenospermia and 31 cases of oligoasthenospermia) and an LC control group (n = 88, including 39 cases of oligozoospermia, 22 cases of asthenospermia and 27 cases of oligoasthenospermia), the former treated with YHC (［0.3 g per capsule］, once 4 capsules, bid, 30 minutes after meal) combined with LC oral liquid (2－3 g/d, tid, at mealtime) and the latter with LC oral liquid only (2－3 g/d, tid, at mealtime). After 3 months of treatment, comparisons were made between the two groups of patients in sperm concentration, the percentages of grade a and grade a+b sperm, and the rate of pregnancy.
Of the 181 patients, 5 in the YHC+LC group and 2 in the LC control group failed to complete the course of treatment. There were no statistically significant differences between the two groups of patients in the baseline sperm concentration and the percentages of grade a and grade a+b sperm (P > 0.05), wich were all markedly increased in both the YHC+LC and the LC control groups (P < 0.05) after 3 months of treatment. And the patients of the YHC+LC group, compared with the controls, showed even more significant increases, as the oligozoospermia patients in sperm concentration (［21.07 ± 6.98］ vs ［16.56 ± 1.82］ ×10⁶/ml, P < 0.05) and the percentages of grade a sperm (［27.53 ± 3.34］% vs ［26.88 ± 1.35］%, P < 0.05) and grade a+b sperm (［53.32 ± 3.16］% vs ［52.63 ± 2.48］%, P < 0.05), the asthenospermia patients in sperm concentration (［26.36 ± 3.37］ vs ［24.42 ± 2.21］ ×10⁶/ml, P < 0.05) and the percentages of grade a sperm (［25.28 ± 4.64］% vs ［21.32 ± 3.28］%, P < 0.05) and grade a+b sperm (［49.19 ± 2.87］% vs ［45.64 ± 1.78］%, P < 0.05), and the oligoasthenospermia patients in sperm concentration (［19.38 ± 3.39］ vs ［18.75 ± 1.35］ ×10⁶/ml, P < 0.05) and the percentages of grade a sperm (［22.65 ± 4.81］% vs ［21.31 ± 2.42］%, P < 0.05) and grade a+b sperm (［48.74 ± 5.61］% vs ［44.36 ± 1.32］%, P < 0.05). The pregnancy rate was dramatically higher in the YHC+LC than in the LC control group (36.4% ［32/88］ vs 15.1% ［13/86］, P < 0.01).
Yihechun Capsules combined with Levocarnitine oral liquid is evidently effective for the treatment of oligozoospermia and asthenospermia.
观察益和春胶囊（YHC）治疗少弱精子症的临床疗效。
将181例男性不育患者随机分为YHC+左卡尼汀（LC）组（n = 93，其中少精子症42例、弱精子症20例、少弱精子症31例）和LC对照组（n = 88，其中少精子症39例、弱精子症22例、少弱精子症27例），前者采用YHC（每粒0.3 g，每次4粒，每日2次，饭后30分钟服用）联合LC口服液（2～3 g/d，每日3次，进餐时服用）治疗，后者仅采用LC口服液（2～3 g/d，每日3次，进餐时服用）治疗。治疗3个月后，比较两组患者的精子浓度、a级和a + b级精子百分比及妊娠率。
181例患者中，YHC+LC组5例、LC对照组2例未完成疗程。两组患者治疗前精子浓度、a级和a + b级精子百分比比较，差异无统计学意义（P > 0.05），治疗3个月后两组上述指标均明显升高（P < 0.05）。与对照组比较，YHC+LC组患者精子浓度升高更显著，少精子症患者精子浓度（［21.07 ± 6.98］ vs ［16.56 ± 1.82］×10⁶/ml，P < 0.05）、a级精子百分比（［27.53 ± 3.34］% vs ［26.88 ± 1.35］%，P < 0.05）及a + b级精子百分比（［53.32 ± 3.16］% vs ［52.63 ± 2.48］%，P < 0.05）升高，弱精子症患者精子浓度（［26.36 ± 3.37］ vs ［24.42 ± 2.21］×10⁶/ml，P < 0.05）、a级精子百分比（［25.28 ± 4.64］% vs ［21.32 ± 3.28］%，P < 0.05）及a + b级精子百分比（［49.19 ± 2.87］% vs ［45.64 ± 1.78］%，P < 0.05）升高，少弱精子症患者精子浓度（［19.38 ± 3.39］ vs ［18.75 ± 1.35］×10⁶/ml，P < 0.05）、a级精子百分比（［22.65 ± 4.81］% vs ［21.31 ± 2.42］%，P < 0.05）及a + b级精子百分比（［48.74 ± 5.6
